摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2R)-2-[(4-ethylphenoxy)methyl]oxirane

中文名称
——
中文别名
——
英文名称
(2R)-2-[(4-ethylphenoxy)methyl]oxirane
英文别名
——
(2R)-2-[(4-ethylphenoxy)methyl]oxirane化学式
CAS
——
化学式
C11H14O2
mdl
——
分子量
178.231
InChiKey
AQKZSTFCPAOFIV-NSHDSACASA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    13
  • 可旋转键数:
    4
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.45
  • 拓扑面积:
    21.8
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (2R)-2-[(4-ethylphenoxy)methyl]oxiraneRuCl2(1,3-dimesityl-imidazolidin-2-yl)(PCy3)(=CHPh)copper(l) iodide 、 magnesium sulfate 、 三乙胺 作用下, 以 四氢呋喃二氯甲烷 为溶剂, 反应 17.17h, 生成 (R)-6-((4-ethylphenoxy)methyl)-5,6-dihydro-2H-pyran-2-one
    参考文献:
    名称:
    A low toxic CRM1 degrader: Synthesis and anti-proliferation on MGC803 and HGC27
    摘要:
    Chromosome region maintenance 1 (CRM1) is the sole nuclear exporter of several tumor suppressor, a growth regulatory protein as an attractive cancer drug target. In the present work, a novel CRM1 degrader was discovered from newly synthesized alpha, beta-unsaturated-delta-lactone based on a natural product Goniothalamin. It induces apoptosis of both MGC803 and HGC27 cell lines via degrading CRM1. Selective inhibition was observed for the proliferation of gastric cancer cell lines MGC803, HGC27 comparing to Human Gastric Mucosal Epithelial Cell Line (GES1). For the first time, CRM1 inhibitor or degrader inducing apoptosis in gastric carcinoma was investigated. (C) 2020 Elsevier Masson SAS. All rights reserved.
    DOI:
    10.1016/j.ejmech.2020.112708
  • 作为产物:
    参考文献:
    名称:
    FRANCOTTE, ERIC;WOLF, ROMAIN M., CHIRALITY, 2,(1990) N, C. 16-31
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • Novel lapachone compounds and methods of use thereof
    申请人:Ashwell Mark A.
    公开号:US20090105166A1
    公开(公告)日:2009-04-23
    The present invention provides novel tricyclic spiro-oxathiine naphthoquinone derivatives, a synthetic method for making the derivatives, and the use of the derivatives to induce cell death and/or to inhibit proliferation of cancer or precancerous cells. The naphthoquinone derivatives of the present invention are related to the compound known as β-lapachone (3,4-dihydro-2,2-dimethyl-2H-naphtho(1,2-b)pyran-5,6-dione).
    本发明提供了一种新型的三环螺-氧杂硫杂萘醌衍生物,一种制造该衍生物的方法,以及利用该衍生物诱导细胞死亡和/或抑制癌症或前癌细胞增殖的应用。本发明的萘醌衍生物与被称为β-拉帕醇(3,4-二氢-2,2-二甲基-2H-萘(1,2-b)吡喃-5,6-二酮)的化合物有关。
  • Novel Lapachone Compounds And Methods of Use Thereof
    申请人:Ashwell Mark A.
    公开号:US20110105470A1
    公开(公告)日:2011-05-05
    The present invention provides novel tricyclic spiro-oxathiine naphthoquinone derivatives, a synthetic method for making the derivatives, and the use of the derivatives to induce cell death and/or to inhibit proliferation of cancer or precancerous cells. The naphthoquinone derivatives of the present invention are related to the compound known as β-lapachone (3,4-dihydro-2,2-dimethyl-2H-naphtho(1,2-b)pyran-5,6-dione).
    本发明提供了新型三环螺环氧硫噻吩萘醌衍生物、制备该衍生物的合成方法以及使用该衍生物诱导细胞死亡和/或抑制癌症或癌前细胞增殖。本发明的萘醌衍生物与已知的β-萘醌化合物(3,4-二氢-2,2-二甲基-2H-萘(1,2-b)吡喃-5,6-二酮)相关。
  • Lapachone compounds and methods of use thereof
    申请人:ArQule, Inc.
    公开号:US08039503B2
    公开(公告)日:2011-10-18
    The present invention provides novel tricyclic spiro-oxathiine naphthoquinone derivatives, a synthetic method for making the derivatives, and the use of the derivatives to induce cell death and/or to inhibit proliferation of cancer or precancerous cells. The naphthoquinone derivatives of the present invention are related to the compound known as β-lapachone (3,4-dihydro-2,2-dimethyl-2H-naphtho(1,2-b)pyran-5,6-dione).
    本发明提供了新型三环螺内醚氧硫噻吩萘醌衍生物、制备该衍生物的合成方法以及利用该衍生物诱导细胞死亡和/或抑制癌症或癌前细胞增殖的用途。本发明的萘醌衍生物与β-萘醌(3,4-二氢-2,2-二甲基-2H-萘(1,2-b)吡喃-5,6-二酮)有关。
  • 5-HT1F antagonists
    申请人:ELI LILLY AND COMPANY
    公开号:EP0976746A1
    公开(公告)日:2000-02-02
    This invention provides 5-HT1f antagonists of Formula I: where AR1, AR2, R, and R' are as defined in the specification.
    本发明提供了式 I 的 5-HT1f 拮抗剂: 其中 AR1、AR2、R 和 R' 如说明书中所定义。
  • Use of 5HT-1F receptor antagonists for treating anxiety disorders
    申请人:ELI LILLY AND COMPANY
    公开号:EP0976747A2
    公开(公告)日:2000-02-02
    The present invention provides a method for the treatment of prevention of anxiety disorders which comprises administering to a mammal in need of such treatment a serotonin 5-HT1F receptor antagonist.
    本发明提供了一种治疗和预防焦虑症的方法,该方法包括向需要治疗的哺乳动物施用5-羟色胺5-HT1F受体拮抗剂。
查看更多